<p>A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells</p>

Abstract

Background Retinoblastoma (Rb) is one of the most common malignancies among children. Following early diagnosis and prompt treatment, the clinical outcome or prognosis of Rb is promising. However, the prognosis or survival rates of patients with late-stage Rb remain poor. Current therapeutic strategies for advanced Rb mainly involve the use of advanced chemotherapeutic options. However, the efficacy of these strategies is not satisfactory. Therefore, the development of novel strategies to achieve a more effective antitumor effect on late-stage Rb is of crucial importance. Methods and materials Topotecan was dissolved in phosphate-buffered saline and prepared into a temperature-sensitive phase-change hydrogel (termed Topo-Gel). Moreover, Topo-Gel was injected into tumor tissues formed by Y79 cells (an Rb cell line) in nude mice to examine the long-term release and long-acting antitumor effect of Topo-Gel on Rb tumors. Results Topo-Gel transforms from liquid to a hydrogel at near body temperatures (phase-change temperature [T 1/2 ] was 37.23±0.473 °C), and maintains the slow release of topotecan in Rb tumor tissues. Following the subcutaneous injection of Topo-Gel, the treatment induced long-acting inhibition of tumor growth and relieved the adverse effects associated with topotecan. Topo-Gel, a temperature-sensitive phase-change hydrogel, is a slow-release system that prolongs the presence of topotecan in Rb tissues, and preserves the efficacy of topotecan in the long term. Conclusion Preparation of topotecan into a temperature-sensitive phase-change hydrogel achieves a long-term sustained antitumor effect on Rb cells, and may be a useful strategy for the treatment of intraocular Rb.

Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging

“…Moreover, the body weight, hematological parameters, and mass of the main organs of animals (nude mice or the immunodeficiency rat) were examined according to the methods descripted by Huo et al. ( 32 ).…”

A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma

“…The aerobic glycolysis of the tumor tissues were measured following the methods described by Yin et al (42). The body-weights or the liver-weights of Immunodeficiency rat were examined (24)(25)(26)(27).…”

“…First, most patients with HCC in China have intolerable cirrhosis, the patient's gastrointestinal function is insufficient/impaired, which results in such patients having poor absorption of oral drugs (22,23). Secondly, oral administration or intravenous infusion as the route of administration will cause the drug to be distributed systemically, which will not only interferes with the physical uptake of glucose of the human body, but also results in negligible dose of BAY-876 at the lesion site of HCC (24)(25)(26)(27). Therefore, the aim of this study was to establish a long-acting and sustained-release formulation of BAY-876 to achieve precise dose administration, and exert targeted anti-tumor activity at HCC lesions without affecting normal tissues and organs.…”

GDF15 Promotes Corneal Neovascularization and Retinoblastoma Cell Progression via AKT/ERK Signal Pathway

“…Twenty days later, we sacri ced the mice were through cervical dislocation and harvested tumors. We applied precision balances to measure tumor weights and calculated tumor volumes as length × width × width/2 [19].…”